Macrogenics (MGNX) closed at $2.29 on November 12, 2026, down 1.3% from the previous close, on volume of 823,522 shares (30-day average 875,787).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Stifel Nicolaus Sticks to Its Hold Rating for MacroGenics (MGNX)
TipRanks (Fri, 13-Nov 9:05 AM ET)
MacroGenics GAAP EPS of -$0.32 misses by $0.28, revenue of $18.67M misses by $20.51M
Seeking Alpha News (Thu, 12-Nov 4:39 PM ET)
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Globe Newswire (Thu, 12-Nov 4:01 PM ET)
MacroGenics to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Globe Newswire (Tue, 3-Nov 4:05 PM ET)
MacroGenics spotlights a 25% response signal for lorigerlimab in clear cell gynecologic cancer
Market Chameleon (Tue, 27-Oct 7:39 AM ET)
Globe Newswire (Mon, 26-Oct 7:06 AM ET)
Globe Newswire (Fri, 23-Oct 9:15 AM ET)
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Wed, 9-Sep 4:05 PM ET)
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
Macrogenics trades on the NASDAQ stock market under the symbol MGNX.
As of November 13, 2026, MGNX stock price declined to $2.16 with 181,703 million shares trading.
MGNX has a beta of 0.78, meaning it tends to be less sensitive to market movements. MGNX has a correlation of 0.01 to the broad based SPY ETF.
MGNX has a market cap of $137.59 million. This is considered a Micro Cap stock.
Last quarter Macrogenics reported $19 million in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-25 million and missed earnings estimates by -$.22.
In the last 3 years, MGNX traded as high as $21.88 and as low as $.99.
The top ETF exchange traded funds that MGNX belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.
MGNX has outperformed the market in the last year with a return of +46.9%, while the SPY ETF gained +10.8%. However, in the most recent history, MGNX shares have underperformed the stock market with its stock returning -46.3% in the last 3 month period and -9.2% for the last 2 week period, while SPY has returned -2.7% and -2.5%, respectively.
MGNX support price is $2.15 and resistance is $2.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGNX shares will trade within this expected range on the day.
